Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region

Clinicopathological Assessment of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04134832

Enrollment

250

Registered

2019-10-22

Start date

2019-06-27

Completion date

2020-06-30

Last updated

2019-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neuroendocrine Tumor

Keywords

Pancreatic neuroendocrine tumors, Neutrophil-to-lymphocyte ratio

Brief summary

Pancreatic Neuroendocrine tumors and carcinomas (pNET) see the last year their incidence and prevalence going up. On the basis of their grade of differentiation and proliferation ratio measured Ki67 staining, there are divided into 3 grade groups : Grade 1 with Ki67 between 1 and 3%, Grade 2 between 3 and 20% and well-differentiated neuroendocrine grade tumors 3 with KI67 greater than 20%, so undifferentiated carcinomas. pNET is a heterogenous group of tumors with variable prognosis. The aim of this study is to identify the prognostic factors in this population, as well the place of neutrophil-to-lymphocyte ratio as a prognostic marker. The primary endpoint is the description of clinic and pathological parameters of patients from Alsace. The secondary endpoints are the identification of prognostic factors in this population

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Major topic ((≥18 years) 2. Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma 3. Subject with tumours or neuroendocrine carcinoma of the pancreas at any stage of the disease. 4. Subject covered in one of the participating centres between 01/01/2008 and 01/01/2019 5. Have a pre-therapeutic biological check-up 6. Subject who has not expressed opposition to the use of his or her data for research purposes

Exclusion criteria

1. Subject who expressed opposition to participate in the study 2. Lack of histological data 3. Minor subject 4. Patient under the protection of justice 5. Subject under guardianship or trusteeship

Design outcomes

Primary

Measure	Time frame
The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.	The participant will be followed-up for a maximum of 11 years, and 1 year at least.

Countries

France

Contacts

Primary ContactGabriel MALOUF, MD, PhD

gabriel.malouf@chru-strasbourg.fr33 3 88 11 62 22

Outcome results